FGFR2 and cholangiocarcinoma: Based on these studies, ctDNA sequencing could potentially improve the clinical management of CCA patients, though the low sensitivity in the detection of translocations, in particular in the FGFR2 gene, still poses a challenge and needs further experimental and clinical validations to demonstrate the clinical utility of ctDNA profiling in the management of CCA.